In Vitro Killing of Canine Urinary Tract Infection Pathogens by Ampicillin, Cephalexin, Marbofloxacin, Pradofloxacin, and Trimethoprim/Sulfamethoxazole

Urinary tract infections are common in dogs, necessitating antimicrobial therapy. We determined the speed and extent of in vitro killing of canine urinary tract infection pathogens by five antimicrobial agents (ampicillin, cephalexin, marbofloxacin, pradofloxacin, and trimethoprim/sulfamethoxazole)...

Full description

Bibliographic Details
Main Authors: Joseph M. Blondeau, Shantelle D. Fitch
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Microorganisms
Subjects:
Online Access:https://www.mdpi.com/2076-2607/9/11/2279
Description
Summary:Urinary tract infections are common in dogs, necessitating antimicrobial therapy. We determined the speed and extent of in vitro killing of canine urinary tract infection pathogens by five antimicrobial agents (ampicillin, cephalexin, marbofloxacin, pradofloxacin, and trimethoprim/sulfamethoxazole) following the first 3 h of drug exposure. Minimum inhibitory and mutant prevention drug concentrations were determined for each strain. In vitro killing was determined by exposing bacteria to clinically relevant drug concentrations and recording the log<sub>10</sub> reduction and percent kill in viable cells at timed intervals. Marbofloxacin and pradofloxacin killed more bacterial cells, and faster than other agents, depending on the time of sampling and drug concentration. Significant differences were seen between drugs for killing <i>Escherichia coli</i>, <i>Proteus mirabilis</i>, <i>Enterococcus faecalis</i>, and <i>Staphylococcus pseudintermedius</i> strains. At the maximum urine drug concentrations, significantly more <i>E. coli</i> cells were killed by marbofloxacin than by ampicillin (<i>p</i> < 0.0001), cephalexin (<i>p</i> < 0.0001), and TMP/SMX (<i>p</i> < 0.0001) and by pradofloxacin than by cephalexin (<i>p</i> < 0.0001) and TMP/SMX (<i>p</i> < 0.0001), following 5 min of drug exposure. Rapid killing of bacteria should inform thinking on drug selection for short course therapy for uncomplicated UTIs, without compromising patient care, and is consistent with appropriate antimicrobial use and stewardship principles.
ISSN:2076-2607